This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Vyepti
  • /
  • An Open Label Trial of ALD403 (Eptinezumab) in Chr...
Clinical trial

An Open Label Trial of ALD403 (Eptinezumab) in Chronic Migraine (PREVAIL)

Read time: 1 mins
Last updated:20th Apr 2020
Status: Completed
Identifier: NCT02985398
An Open Label Trial of ALD403 (Eptinezumab) in Chronic Migraine (PREVAIL)

An evaluation of long term safety of repeat ALD403 doses in Chronic Migraine

Study Type: Interventional  (Clinical Trial)
Actual Enrollment: 128 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: An Open Label Trial to Evaluate the Safety of ALD403 Administered Intravenously in Patients With Chronic Migraines
Actual Study Start Date: December 2016
Actual Primary Completion Date: April 2018
Actual Study Completion Date: March 2019

- Experimental:
ALD403 (Eptinezumab) Dose Level 1

Category Value
Study type(s) Interventional
Expected enrolment 128
Actual Study start date 01 December 2016
Actual study completion date 01 March 2019

View full details